🟢 Nyxoah is trading 18.87% up today after ACCCESS U.S. pivotal study meets primary endpoints

Nyxoah is trading at $1.79, +18.87% after its September 2, 2026 ACCCESS U.S. pivotal study met primary safety and efficacy endpoints.

• At 12 months, AHI and ODI responder rates were 77.2% and 87.7%, respectively.
• No device-related serious adverse events were reported.
• Results support potential U.S. Genio indication expansion for complete concentric collapse patients.